
Eyenovia (EYEN) Stock Forecast & Price Target
Eyenovia (EYEN) Analyst Ratings
Bulls say
Eyenovia Inc. is strategically positioned within the ophthalmic sector, leveraging its proprietary array print (MAP) platform technology and the user-filled Optejet system, which enhances the precision and delivery of ophthalmic therapies. The approval and market presence of Mydcombi highlights the effectiveness of the Optejet's delivery method, setting a foundation for potential future growth through additional product approvals and partnerships in untreated conditions such as dry eye disease. Despite a shift in rating and price target, the underlying developments, including ongoing collaborations and the streamlined focus on the Optejet, suggest a favorable outlook for Eyenovia's innovations in smart ophthalmic therapies.
Bears say
Eyenovia Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to the setbacks in product development and commercial viability. Specifically, the failure of the Phase 3 CHAPERONE trial, which aimed to use the Optejet for delivering MicroPineatropine, has raised concerns regarding the company's ability to achieve peak commercial revenue estimates and secure necessary capital resources to support ongoing operations. Furthermore, potential execution challenges related to the pandemic have exacerbated uncertainties regarding program development and commercialization, emphasizing the need for strategic alternatives to enhance the utilization of its delivery technology.
This aggregate rating is based on analysts' research of Eyenovia and is not a guaranteed prediction by Public.com or investment advice.
Eyenovia (EYEN) Analyst Forecast & Price Prediction
Start investing in Eyenovia (EYEN)
Order type
Buy in
Order amount
Est. shares
0 shares